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Abstract Monoclonal antibodies generated against multiple
antigenic peptides of the N-terminal sequence (3LVP-
SARAELQSSPLV17) of the cloned N opioid receptor immuno-
precipitated a 58 kDa protein from CHAPS-solubilized NG108-
15 membranes. The immunoprecipitates bound [3H]DPDPE ^
but not [3H]DAMGO ^ with a Kd of 6.4 nM and a Bmax of
75 pM. Western blot analysis revealed a distinct band of 58 kDa.
The antibodies inhibited basal and PGE1-stimulated cAMP
levels, and mimicked the effect of agonists manifest in a
compensatory increase in cAMP formation. The antibody will
be potentially useful in the analysis of functional epitopes on the
N opioid receptor.
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1. Introduction
The opioid receptors mediate a host of behavioral e¡ects
including antinociception, reward and reinforcement as well
as a number of neuroendocrine responses. Three major classes
of opioid receptors designated W, N and U have been cloned
and identi¢ed as members of the G protein family of seven
transmembrane domain receptors which are negatively
coupled to adenylate cyclase [1^6]. Extensive e¡orts in the
past were made by several investigators to purify the receptor
proteins for elucidating their molecular properties [7^10].
However, all such attempts in the last two decades to obtain
adequate amounts of homogeneous and functionally compe-
tent receptor proteins have been, by and large, unsuccessful.
Studies on site-directed mutagenesis [11,12] and receptor chi-
meras [13] had suggested the involvement of di¡erent receptor
regions in the multiple speci¢city for a variety of ligands re-
sponsible for complex behavioral manifestations. The avail-
ability of monoclonal antibodies will help in the delineation
of functional epitopes on the receptor and provide a valuable
tool for the quantitation of the receptor protein present in the
cells under di¡erent physiological conditions. It will also ful¢l
a long-felt need for a convenient method for the puri¢cation
of the receptor protein for structural studies. In this paper we
report the generation of a functional monoclonal antibody to
the multiple antigenic peptide (MAP) of the N-terminal of the
cloned N opioid receptor. Signi¢cantly, the antibody acts as an
agonist in the dual regulation of adenylate cyclase in NG108-
15 cells.
2. Materials and methods
2.1. Cell growth
NeuroblastomaUglioma hybrid NG108-15 cells were grown in Dul-
becco’s modi¢ed Eagle’s medium (DMEM; Gibco, USA) supple-
mented with hypoxanthine aminopterin thymidine, 10% fetal calf se-
rum (Biological Industries, Israel), streptomycin (100 Wg/ml) and
penicillin (100 U/ml) as previously described [1,10].
2.2. Production of monoclonal antibodies
MAP to the N-terminal sequence (3LVPSARAELQSSPLV17) of the
cloned N opioid receptor was obtained from Research Genetics, USA.
BALB/c mice were injected intraperitoneally (i.p.) with MAP (10 Wg)
emulsi¢ed in Freund’s complete adjuvant. Booster i.p. injections were
given every 15 days with MAP emulsi¢ed in Freund’s incomplete
adjuvant. Three days prior to fusion 10 Wg MAP was injected intra-
venously (i.v.). Mice were bled and serum collected for polyclonal
antisera. The spleens from the immunized mice were fused with
SP2/0-Ag14 myeloma cells as described by Dastidar and Sharma
[14]. The positive secreting clones were selected by an ELISA using
pure MAP and NG108-15 cells.
2.3. ELISA
ELISA was carried out by a modi¢cation of the method described
by Sharma et al. [15]. Wells of the ELISA plate were coated with 1 Wg
MAP/1U105 NG108-15 cells in 50 mM Tris-HCl, pH 7.5 by incubat-
ing overnight at 4‡C. Non-speci¢c sites were blocked with 3% BSA in
phosphate-bu¡erd saline (PBS) for 1 h at 37‡C. Wells were incubated
overnight at 4‡C with hybridoma culture supernatant or growth me-
dium from Sp2/0-Ag14 as control. Plates were washed thrice with PBS
and incubated with goat anti-mouse IgG coupled to peroxidase for 1 h
at room temperature. Color was developed using ortho-phenylenedi-
amine (0.5 mg/ml in 0.15 M citrate phosphate bu¡er, pH 5.0) and
H2O2 (0.03%) and the reaction was terminated after 10 min by addi-
tion of 5 N H2SO4.
2.4. Puri¢cation of monoclonal antibodies
2.4.1. Ammonium sulfate precipitation. Saturated ammonium sul-
fate solution was added to the hybridoma culture supernatant to bring
the ¢nal concentration to 50%. The solution was stirred gently at 4‡C
overnight and centrifuged at 3000Ug for 30 min. The pellet was dis-
solved in 0.1 volume of the starting volume in PBS, dialyzed exten-
sively against PBS, centrifuged and the protein concentration was
determined by Bradford’s method [16].
2.4.2. Puri¢cation on protein A-Sepharose CL-4B column (high
salt). Monoclonal antibodies were puri¢ed by a modi¢cation of
the method of Ey et al. [17]. Concentration of NaCl in the hybridoma
culture supernatant was adjusted to 3.3 M and 1/10 volume of 1 M
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sodium borate (pH 8.9) was added. The solution was passed through
a protein A-Sepharose CL-4B (Pharmacia, Sweden) bead column. The
beads were washed with 10 column volumes each of 3 M NaCl, 50
mM sodium borate (pH 8.9) and 3 M NaCl, 10 mM sodium borate
(pH 8.9). Antibody was eluted with 100 mM glycine (pH 3.0). The
eluates were collected in tubes containing 50 Wl of 1 M Tris-HCl (pH
8.0). Fractions containing immunoglobulin were identi¢ed by absorb-
ance at 280 nm, and protein was determined by Bradford’s method
[16].
2.5. Solubilization of the N opioid receptor
Membranes from NG108-15 cells were prepared and the receptor
solubilized as described by Gomathi and Sharma [10]. In brief, mem-
branes were washed by incubating with 50 mM Tris-HCl, pH 7.5
containing 1 mM phenylmethylsulfonyl £uoride (PMSF; Sigma,
USA) for 30 min at 37‡C and solubilized using 10 mM 3-[(3-chol-
amidopropyl) dimethyl ammonio] 1-propane-sulfonate (CHAPS) (Sig-
ma, USA). For immunoprecipitation the CHAPS-solubilized extract
was diluted to 1 mM CHAPS with 50 mM Tris-HCl, pH 7.5.
2.6. Immunoprecipitation
Protein (A+G)-agarose beads (Calbiochem, USA), 10 Wl, were sus-
pended in 1 ml TBS (20 mM Tris-HCl, pH 7.4 with 150 mM NaCl)
and washed three times in TBS by centrifugation at 10 000 rpm for
1 min. To 100 Wl of beads suspended in TBS, 100 Wg monoclonal
antibody (puri¢ed by ammonium sulfate precipitation) or 100 Wg
mouse IgG was added. The tubes were incubated for 1 h at room
temperature with gentle shaking, followed by centrifugation at 10 000
rpm for 1 min and washing with TBS three times. To the antibody- or
mouse IgG-coated beads, 70 Wl of solubilized receptor (1 mM
CHAPS, 200 Wg protein) was added. Receptor-antibody complexes
were incubated overnight at 4‡C with mild shaking. Samples were
centrifuged at 10 000 rpm for 1 min and supernatant was saved for
assay of residual binding. The beads were washed three times with
TBS and three times with bu¡er A (50 mM Tris-HCl, pH 7.5 with
1 mM CHAPS and 1 mM PMSF). The pellet containing the immu-
noprecipitates was used for binding of opiates.
2.7. Opioid receptor binding
Immunoprecipitates obtained as described above or NG108-15
membranes (500^750 Wg protein) were suspended in 50 mM Tris-
HCl, pH 7.5 and binding was measured with [3H]DPDPE (32.4 Ci/
mmol)/[3H]DAMGO (48.9 Ci/mmol) (New England Nuclear, USA)
for 60 min at 37‡C in a ¢nal volume of 300 Wl. Non-speci¢c binding
in the presence of cold DPDPE/DAMGO (National Institute of Drug
Abuse, USA), 10 WM, was 25^30% of total binding. Incubation was
terminated by rapid ¢ltration through Whatman GF/B ¢lters. Filters
were washed with 3U5 ml of ice-cold Tris-HCl (50 mM, pH 7.5),
dried and radioactivity determined in a toluene-based scintillation
£uid.
2.8. Western blot
Western blots were performed as described by Dastidar and Sharma
[14]. NG108-15 cells were washed with sterile PBS three times and
preheated sample bu¡er (50 mM Tris-HCl (pH 6.8), 100 mM dithio-
threitol, 2% SDS, 10% glycerol, 0.1% bromophenol blue) at 100‡C
was added. The samples were kept at 100‡C for 3 min, followed by
centrifugation at 10 000Ug for 5 min. The supernatant was electro-
phoresed on sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gels
at 125 V for 90 min. The protein bands were electrotransferred onto
polyvinylidene di£uoride Immobilon-P membranes (Millipore, USA)
for 90 min at 150 mA. The membranes were blocked for 1 h in TTBS
(20 mM Tris-HCl, pH 7.4, and 150 mM NaCl containing 0.2% (v/v)
Tween-20) at room temperature. Membranes were incubated with Nt-
Ab (polyclonal antiserum) to MAP or normal mouse IgG (1:100 in
TTBS) for 16 h at 4‡C and washed ¢ve times (5 min each) in TTBS
followed by exposure to secondary antibody (sheep anti-mouse con-
jugated to HRPO, 1:1000 in TTBS) (Gibco, USA) for 1 h at room
temperature. Membranes were washed ¢ve times (5 min each) with
TTBS followed by incubation for 1 h at room temperature with strep-
tavidin-HRPO conjugate (1:1500 in TTBS) (Gibco, USA). Mem-
branes were washed 5 times with TTBS (5 min each) and developed
using ECL Kit (Amersham, UK). Western blots were also performed
using 5 Wg a⁄nity-puri¢ed N-terminal antibody in TTBS as the pri-
mary antibody and goat anti-mouse conjugated with alkaline phos-
phatase (1:5000 dilution of 0.4 mg/ml stock in TTBS) as the secon-
dary antibody. In this case membranes were incubated in 5-bromo-4-
chloro-3-indolyl phosphate/nitroblue tetrazolium (chromogenic) re-
agent (Kirkegaard and Perry Laboratories, USA) to visualize the
immunoreactive bands.
2.9. Immuno£uorescence
NG108-15 cells (1U103) were plated on poly-L-lysine-coated cover-
slips (Sigma, USA) and immuno£uorescence was performed as de-
scribed by Goswami et al. [18] using Nt-Ab (polyclonal antiserum)
as the primary antibody (1:20 in PBS) and £uorescein isothiocyanate-
labelled anti-mouse as the secondary antibody (1:100 in PBS).
2.10. Assay of cAMP in intact cells
Con£uent cells (in 60 mm petri dishes) were washed three times
with 5 ml of medium A (DMEM with 25 mM HEPES, pH 7.4) and
incubated in medium A containing 0.5 mM Ro20-1724 for 10 min at
37‡C. The reaction was initiated by the addition of 30 Wl of opiate in
water/30 Wl of PGE1 in ethanol/solvent. Ethanol (0.5% when Ro20-
1724 was used and 1% when Ro20-1724 and PGE1 were used) had no
e¡ect upon cAMP formation. After incubation the medium was dis-
carded and 2 ml 5% TCA with [3H]cAMP (3000 cpm) was added at
4‡C. cAMP was puri¢ed and assayed by the method of Gilman [19] as
modi¢ed by Sharma et al. [1,2]. Values reported for triplicate dishes
were corrected to 100% recovery of cAMP.
3. Results
In these studies three preparations of antibody (Nt-Ab)
were used: (I) the polyclonal antisera (Section 2.2), (ii) mono-
clonal antibody concentrated by ammonium sulfate precipita-
tion of the hybridoma culture supernatant (Section 2.4.1) and
(iii) monoclonal antibody puri¢ed on protein A-Sepharose
CL-4B columns (Section 2.4.2).
The N opioid receptor from NG108-15 membranes was
solubilized in 10 mM CHAPS; the extract diluted to 1 mM
CHAPS was incubated with Nt-Ab-coated protein (A+G)-
agarose beads. The immunoprecipitates thus obtained were
used for binding of [3H]DPDPE and [3H]DAMGO. Equiva-
lent amounts of the solubilized receptor protein were also
used as a suitable reference. The immunoprecipitates bound
more than 70 fmol of [3H]DPDPE, with only 20 fmol of
residual binding left in the supernatant. [3H]DAMGO, the W
opioid receptor-speci¢c ligand, did not bind to the immuno-
precipitated receptor. Immunoprecipitates obtained with nor-
Table 1
Binding of [3H]DPDPE/[3H]DAMGO to the receptor in Nt-Ab im-
munoprecipitates
Receptor Speci¢c binding (fmol)
[3H]DPDPE [3H]DAMGO
Receptor-Nt-Ab
Pellet 78.6 1.26
Supernatant 20.7 2.21
Receptor-mouse IgG
Pellet 5.52 0.72
Supernatant 90.5 3.36
CHAPS solubilized receptor 154.7 5.13
NG108-15 membranes were solubilized using CHAPS. To 200 Wg of
solubilized protein 200 Wg of Nt-Ab (ammonium sulfate precipitate)/
normal mouse IgG coupled to protein (A+G)-agarose beads was
added. The receptor antibody complex bound to the beads was col-
lected by centrifugation and diluted with the binding bu¡er. Binding
assays were performed with aliquots of the immunoprecipitate,
supernatant and equivalent amount (200 Wg) of CHAPS solubilized
receptor protein as described in Section 2. Concentrations of
[3H]DPDPE and [3H]DAMGO were 5 nM and of cold DPDPE/
DAMGO 10 WM. Values shown are the average of two experiments
performed in triplicate.
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mal mouse IgG did not show any binding with [3H]DPDPE
(Table 1). The Kd and Bmax for [3H]DPDPE binding to the
Nt-Ab immunoprecipitates were estimated to be 6.4 nM and
75 pM, respectively, from the Scatchard plot shown in Fig. 1.
Fig. 2 shows the inhibitory e¡ect of Nt-Ab on the binding
of [3H]DPDPE to NG108-15 membranes as a function of its
concentration. Maximal inhibition by the antibody under the
conditions of our experiment was discernible at 15 Wg of the
antibody, with 50% inhibition at 4 Wg. Normal mouse IgG,
serving as a control, elicited no inhibition as shown by the
dotted line.
Results of the Western blot analysis are shown in Fig.
3A,B. Two distinct bands ^ a major one at 58 kDa and a
minor one at 30^38 kDa ^ are clearly identi¢able (Fig. 3A)
using the Nt-Ab (polyclonal antisera). A⁄nity-puri¢ed mono-
clonal antibody also revealed the presence of the same two
bands (Fig. 3B).
We next examined the e¡ects of the monoclonal antibody
(Nt-Ab) on intact NG108-15 cells, with particular reference to
its modulatory in£uence on the basal and PGE1-stimulated
cAMP formation. As seen in Table 2 Nt-Ab (ammonium sul-
fate precipitate) inhibited the basal level of cAMP by 38% and
the PGE1-stimulated levels by 49%. Naloxone partially re-
versed the Nt-Ab-induced inhibition by 25% in the case of
basal and by 35% in the case of PGE1-stimulated cAMP lev-
els. The presence of both morphine and Nt-Ab elicited no
additive inhibition of basal and PGE1-stimulated cAMP lev-
els. Normal mouse IgG did not show any e¡ect. The inhib-
itory e¡ect of Nt-Ab on PGE1-stimulated cAMP formation
was found to be concentration-dependent (Fig. 4). Opioids ^
morphine and etorphine ^ are known to lead to a compensa-
tory increase in the levels of cAMP in NG108-15 cells. Data
presented in Table 3 indicated that the e¡ect of the Nt-Ab
follows similar trend. Addition of 5Wg of a⁄nity-puri¢ed
monoclonal antibody resulted in 38% compensatory increase
in cAMP formation in comparison to 63% increase in the
presence of morphine.
Further con¢rmation of the fact that the antibody (Nt-Ab)
is indeed directed speci¢cally towards N receptors came from
immuno£uorescence studies on NG108-15 and C6 glioma
cells. As seen in Fig. 5, while NG108-15 cells gave strong
membranous £uorescence (A), C6 glioma cells lacking N re-
ceptors gave no signal (B). Control cells treated with preim-
mune sera also showed no £uorescence (C).
4. Discussion
We report the generation of a monoclonal antibody against
the amino-terminal 3^17 sequence of the cloned N opioid re-
ceptor, which immunoprecipitated the N opioid receptor in
Fig. 1. Scatchard analysis of [3H] DPDPE speci¢c binding to Nt-Ab
immunoprecipitates. Binding assays with the N-speci¢c ligand
[3H]DPDPE (¢nal concentration 1^20 nM) were carried out with
the immunoprecipitates obtained from CHAPS solubilized NG108-
15 membranes and Nt-Ab (ammonium sulfate precipitate) as de-
scribed in Section 2. Non-speci¢c binding was determined in the
presence of cold DPDPE (10 WM) and was 20^30% of the total
binding. Each value represents the average of two experiments per-
formed in triplicate.
Fig. 2. Competitive inhibition of [3H]DPDPE binding to N opioid
receptors by Nt-Ab. Speci¢c binding of [3H] DPDPE (¢nal concen-
tration 10 nM) to NG108-15 membranes (750 Wg) was carried out
in the presence of varying amounts of Nt-Ab (a⁄nity-puri¢ed) (b) ;
normal mouse IgG (a). Non-speci¢c binding was determined in the
presence of cold DPDPE (10 WM) and was 20^30% of the total
binding. Each value is the average of two experiments performed in
triplicate.
Table 2
Inhibition of basal and PGE1-stimulated cAMP formation in
NG108-15 cells by Nt-Ab and its reversal by naloxone
Additions pmol of cAMP formed/mg protein
No addition 167
Nt-Ab 104
Nt-Ab+naloxone 144
Morphine 94
Nt-Ab+morphine 102
PGE1 3900
Nt-Ab+PGE1 1980
Nt-Ab+PGE1+naloxone 3200
Morphine+PGE1 1990
Nt-Ab+morphine+PGE1 1930
Mouse IgG+PGE1 3680
NG108-15 cells (P15) were plated in 60 mm petri dishes. When 80%
con£uent, the medium was removed, cells were washed quickly with
DMEM-HEPES and incubated with di¡erent e¡ector agents as de-
scribed in Section 2. Concentrations of e¡ector agents were: Nt-Ab
(ammonium sulfate precipitate); 200 Wg; normal mouse IgG, 200
Wg; morphine, 10 WM; PGE1, 10 WM; naloxone, 10 WM. Each value
is the average of two experiments performed in triplicate.
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CHAPS-solubilized NG108-15 cellular membranes. The im-
munoprecipitates retain speci¢c binding of [3H]DPDPE with
a Kd of 6.4 nM and a Bmax of 75 pM, which was in the same
range as reported by us earlier [10]. NG108-15 cells express
only the N opioid receptors and the immunoprecipitates did
not bind to W-speci¢c ligands like [3H]DAMGO. This is highly
reassuring as regards the speci¢city of the binding of
[3H]DPDPE to the immunoprecipitates. A detailed investiga-
tion revealed a dose-dependent inhibition of basal and PGE1-
stimulated cAMP formation by the Nt-Ab. Naloxone reversed
this inhibition by 25 and 35%, respectively. It is interesting to
note that the monoclonal antibody (Nt-Ab) also mimicked the
e¡ect of opioid agonists in bringing about a compensatory
increase in cAMP. The N-terminal of the N-opioid receptor
is known to be in the extracellular domain, along with several
loops [23]. Therefore, the observed inhibitory e¡ect of the
monoclonal antibody (Nt-Ab) on the binding of [3H]DPDPE
to NG108-15 cells is not entirely unexpected. However, this
does not necessarily imply that the epitope recognized by Nt-
Ab coincides with the binding site of [3H]DPDPE. The anti-
bodies, being bulky molecules, may in£uence the ligand bind-
ing by steric hindrance. This question can only be settled by
the delineation of the epitope recognized by Nt-Ab, and of the
binding sites for the ligands. The point we wish to emphasize
here is that monoclonal antibody (Nt-Ab) acts as an opioid
agonist and facilitates signal transduction as inferred from its
modulatory in£uence on the levels of cAMP, by bringing
about subtle conformational changes in the receptor. Cucumel
and Cupo [20] showed that anti-idiotypic antiserum (against
antibodies directed against DSLET) inhibited the binding of
[3H]DADLE and mimicked inhibitory e¡ects of the agonist
on cAMP levels in NG108-15 cells, but did not discriminate
between W and N opioids. On the other hand, Nt-Ab obtained
in this study is not only speci¢c for N receptors but also acts as
a potent opioid agonist. The reversal of its inhibitory e¡ect by
naloxone is understandable, in view of the high a⁄nity of the
antagonist for the receptor.
Several investigators have used antibodies against opioid
receptors which elicited non-speci¢c interactions with several
proteins as revealed by Western blot analysis [20^22]. In con-
trast, both polyclonal antisera and the monoclonal Nt-Ab
Fig. 4. Inhibition of PGE1-stimulated cAMP formation as a func-
tion of Nt-Ab concentration. NG108-15 cells (P15) were plated in
60 mm petri dishes. When 80% con£uent, the medium was removed,
cells were washed quickly with DMEM-HEPES and incubated as
described in Section 2. Concentrations of e¡ector agents were: Nt-
Ab (a⁄nity-puri¢ed), 0^5 Wg; PGE1, 10 WM. Each value is the aver-
age of two experiments performed in triplicate.
Table 3
E¡ect of Nt-Ab on opiate-induced compensatory increase in cAMP
formation in NG108-15 cells
Additions pmol cAMP formed/mg protein
No addition 1359
Morphine 2218
Nt-Ab 1871
Nt-Ab+morphine 2148
Etorphine 2529
Nt-Ab+etorphine 2353
NG108-15 cells (P15) were plated in 60 mm petri dishes. When 80%
con£uent, medium was removed and 2 ml fresh medium with mor-
phine, 10 WM; Nt-Ab (a⁄nity-puri¢ed) 5 Wg; etorphine, 1.6 WM
was added. Fresh Nt-Ab was added every 24 h. After 48 h the me-
dium was removed, the monolayer was washed quickly in DMEM-
HEPES three times and incubated in DMEM-HEPES with nalox-
one, 10 WM for cAMP formation as described in Table 2. Normal
mouse IgG, 5 Wg, when added during growth had no e¡ect (data
not shown). Each value is the average of three experiments per-
formed in duplicate.
Fig. 3. Western blot analysis of CHAPS solubilized NG108-15
membranes. Whole NG108-15 cell lysates (A) or NG108-15 mem-
branes solubilized with CHAPS (B) were subjected to SDS-PAGE
followed by transfer to Immobilon-P membranes as described in
Section 2. A: Lane 1, ECL markers; 2, Nt-polyclonal antiserum; 3,
pre-immunized mouse serum. B: Lane 1, Nt-Ab (a⁄nity-puri¢ed);
2, normal mouse IgG.
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(a⁄nity-puri¢ed) to the N opioid receptor reported here rec-
ognized a major protein of 58 kDa (Fig. 3A,B) in NG108-15
membranes. These observations were further substantiated by
strong membranous £uorescence exhibited by the Nt-Ab on
NG108-15 cells (Fig. 5A). In view of its high speci¢city and
strong binding to N opioid receptor protein, the Nt-Ab is
potentially useful in the preparation of large amounts of the
receptor by a⁄nity columns. In addition, it provides a valua-
ble tool for studying the expression of the opioid receptor in
brain under di¡erent physiological conditions.
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